Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Treatment and Dose Optimization in HR+/HER2- Early Breast Cancer

July 18th 2023

A comprehensive discussion on approaches to optimizing treatment selection and dosing in HR+/HER2- breast cancer.

Dr Tarantino on the Expansion of Treatment Options Post-CDK4/6 Inhibition in HR+ Breast Cancer

July 17th 2023

Paolo Tarantino, MD, discusses the expansion and selection of effective treatment options for patients with hormone receptor-positive breast cancer who progressed on a CDK 4/6 inhibitor.

Dr Sammons on the SONIA Trial of First-Line CDK4/6 Inhibitor Use in HR+/HER2– Breast Cancer

July 14th 2023

Sarah Sammons, MD, discusses whether CDK4/6 inhibitors should be considered a standard first line treatment within hormone receptor–positive, HER2-negative advanced breast cancer according to primary results from the phase 3 SONIA trial.

Age-Dependent Results With CDK 4/6 Inhibitors

July 13th 2023

Experts in breast oncology review age-dependent outcomes with CDK 4/6 inhibitors.

Data Updates and Ongoing Trials in the HER2+ Adjuvant Space

July 13th 2023

Panelists discuss recent data updates on standard-of-care and emerging regimens for adjuvant treatment of HER2+ eBC, including data presented at the 2023 ASCO meeting, and highlight exciting trials in progress that have not yet read out.

Ongoing Research in HER2+ Metastatic Breast Cancer

July 13th 2023

An overview of agents and treatment strategies currently being investigated in HER2+ metastatic breast cancer.

Individualizing Care with CDK 4/6 Inhibitors

July 13th 2023

Stephanie Graff, MD, and Rachel Layman, MD, discuss how to individualize care with CDK4/6 inhibitors in patients with high-risk early breast cancer.

HER2CLIMB-02: Tucatinib and T-DM1 in HER2+ Breast Cancer

July 13th 2023

Megan Kruse, MD, discusses the HER2CLIMB-02 study and the impact it may have on the HER2+ metastatic breast cancer treatment landscape.

Identifying Patients Suitable for Adjuvant Neratinib

July 13th 2023

Drs Tripathy and McArthur touch on the use of extended adjuvant therapy with neratinib and identify patients who might be suitable for this regimen, including those high-risk patients with residual disease after neoadjuvant therapy.

Dr Vega on an Analysis of Outcomes with Axillary Surgery in Breast Cancer Post-Neoadjuvant Chemo

July 12th 2023

Raymond Mailhot Vega, MD, MPH, discusses the efficacy of axillary surgery in patients with breast cancer previously given neoadjuvant chemotherapy, according to findings from a retrospective analysis.

Treatment Guidelines on Fertility Preservation in Breast Cancer

July 12th 2023

Focused discussion on treatment guidelines and recommendations for fertility preservation while treating premenopausal patients with breast cancer.

Monitoring Patients With Breast Cancer Receiving OFS

July 12th 2023

A brief review of monitoring, response assessment, and treatment modification strategies used for patients with breast cancer undergoing OFS. .

Managing Abemaciclib-Associated Toxicities in HR+/HER2- Early Breast Cancer

July 11th 2023

VK Gadi, MD, PhD, shares his strategies for managing adverse events related to abemaciclib in the treatment of HR+/HER2- breast cancer.

Recent Data on Adjuvant Therapies in HR+/HER2- Breast Cancer

July 11th 2023

Experts on HR+/HER2- breast cancer review data updates on adjuvant therapies from the 2023 ASCO Annual Meeting.

Systemic Therapy Shows Increasing Promise for CNS Metastases in Breast Cancer

July 10th 2023

Nancy U. Lin, MD, provides clinical insights on the treatment of patients with breast cancer brain metastases and discusses the advantages and disadvantages of systemic therapy vs radiation therapy for this population.

CDK4/6 Inhibitor Selection and Sequencing Continue to Evolve in HR+ Breast Cancer

July 8th 2023

Sarah Sammons, MD, discusses the evolving role of CDK4/6 inhibitors in hormone receptor–positive breast cancer, the future of antibody-drug conjugates in triple-negative breast cancer, and the importance of educating patients about their available treatment options so they can share in the decision-making process.

Dr. Yuan on Ongoing Research in Patients With TNBC According to Pathologic Response

July 7th 2023

Yuan Yuan, MD, PhD, discusses ongoing investigations at Cedars-Sinai of treatment de-escalation in patients with early-stage triple-negative breast cancer according to their pathological response.

Adjuvant Ibandronate Plus Capecitabine Does Not Significantly Improve OS in Elderly Patients With Early Breast Cancer

July 6th 2023

Although adjuvant treatment with ibandronate plus capecitabine resulted in a numerical improvement in overall survival vs ibandronate alone in elderly patients with moderate or high-risk early breast cancer, this did not reach statistical significance, according to long-term data from the phase 3 ICE study.

Dr Bahadur on the Shift in Frontline CDK4/6 Inhibitor Selection in HR+/ HER2– Breast Cancer Breast Cancer

July 6th 2023

Shakeela Bahadur, MD, discusses how recent data have informed the selection of approved CDK4/6 inhibitors in the frontline setting for patients with metastatic hormone receptor–positive, HER2-negative breast cancer.

Ixabepilone Generates Clinical Benefit in Patients With Metastatic Breast Cancer Selected by Companion Diagnostic

July 6th 2023

Ixabepilone produced clinical benefit in patients with metastatic breast cancer selected for treatment with the DRP®-IXEMPRA® companion diagnostic candidate.